BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 7513262)

  • 1. In vitro expansion of tumor-specific, HLA-restricted human CD8+ cytolytic T lymphocytes.
    Nakashima M; Watanabe T; Koprowski H; Schuchter L; Steplewski Z
    Cell Immunol; 1994 Apr; 155(1):53-61. PubMed ID: 7513262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokine combinations for induction of antigen-specific cytolytic T lymphocytes from peripheral blood lymphocytes.
    Tsujitani S; Nakashima M; Watanabe T; Kaibara N; Koprowski H; Steplewski Z
    Anticancer Res; 1995; 15(3):655-60. PubMed ID: 7645938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of alloreactive cytolytic T lymphocytes by immobilized anti-CD3 monoclonal antibodies. Analysis of requirements for human cytolytic T-lymphocyte differentiation.
    De Jong R; Brouwer M; Rebel VI; Van Seventer GA; Miedema F; Van Lier RA
    Immunology; 1990 Jul; 70(3):357-64. PubMed ID: 2143171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies.
    Wong JT; Pinto CE; Gifford JD; Kurnick JT; Kradin RL
    J Immunol; 1989 Nov; 143(10):3404-11. PubMed ID: 2509557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the cytolytic activity of CD4+ and CD8+ tumor-infiltrating lymphocytes in human renal cell carcinoma.
    Finke JH; Rayman P; Alexander J; Edinger M; Tubbs RR; Connelly R; Pontes E; Bukowski R
    Cancer Res; 1990 Apr; 50(8):2363-70. PubMed ID: 2107973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defective lymphokine production by most CD8+ and CD4+ tumor-specific T cell clones derived from human melanoma-infiltrating lymphocytes in response to autologous tumor cells in vitro.
    Guilloux Y; Viret C; Gervois N; Le Dréan E; Pandolfino MC; Diez E; Jotereau F
    Eur J Immunol; 1994 Sep; 24(9):1966-73. PubMed ID: 7522155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HLA-B-restricted, CD8+ cytolytic human T cell clones derived from a melanoma-invaded lymph node.
    Nakashima M; Watanabe T; Koprowski H; Steplewski Z
    Hybridoma; 1996 Apr; 15(2):147-54. PubMed ID: 8743295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Major histocompatibility complex-unrestricted cytolytic activity of human T cells. Analysis of precursor frequency and effector phenotype.
    Patel SS; Thiele DL; Lipsky PE
    J Immunol; 1987 Dec; 139(11):3886-95. PubMed ID: 3500232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenotypic and functional modulation of interleukin-2-activated peripheral blood mononuclear cells by anti-CD3 and anti-CD28 antibody.
    Yoshino I; Yano T; Miyamoto M; Sugimachi K; Kimura G; Nomoto K
    Lymphokine Cytokine Res; 1993 Aug; 12(4):191-6. PubMed ID: 8218591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells.
    Tilden AB; Itoh K; Balch CM
    J Immunol; 1987 Feb; 138(4):1068-73. PubMed ID: 3100627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.
    McKenzie RS; Simms PE; Helfrich BA; Fisher RI; Ellis TM
    Cancer Res; 1992 Nov; 52(22):6318-22. PubMed ID: 1384959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of memory CD4+, CD8+, CD45RO+ and CD16- lymphocytes activated with IL-2, INF-gamma, and TNF-alpha with specific cytotoxicity against autologous cervical cancer cells in a mixed leukocyte-tumour cell culture.
    Rangel R; Rocha L; Ramirez JL; Ibarra MJ; Solorza G; Monroy A; Ramirez MA; Herrera A; Weiss-Steider B
    Eur Cytokine Netw; 1995; 6(3):195-202. PubMed ID: 8589277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergy between recombinant interleukin 2 (rIL 2) and IL 2-depleted lymphokine-containing supernatants in facilitating allogeneic human cytolytic T lymphocyte responses in vitro.
    Gately MK; Wilson DE; Wong HL
    J Immunol; 1986 Feb; 136(4):1274-82. PubMed ID: 2418110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proliferation, phenotype, and cytotoxicity of human lymphocytes isolated from lymph nodes invaded by melanoma cells.
    Nakashima M; Janiszewska M; Steplewski Z; Watanabe T; Schuchter L; Koprowski H
    Hybridoma; 1994 Jun; 13(3):241-6. PubMed ID: 7927369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of human autologous melanoma-specific cytotoxic T cells from tumor-involved lymph nodes.
    Maeda K; Lafreniere R; McKinnon JG; Jerry LM
    Mol Biother; 1991 Jun; 3(2):95-102. PubMed ID: 1910625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of human B cell proliferation and differentiation by tumor necrosis factor-alpha and interleukin 1.
    Jelinek DF; Lipsky PE
    J Immunol; 1987 Nov; 139(9):2970-6. PubMed ID: 3117883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specificity, T cell receptor diversity and activation requirements of CD4+ and CD8+ clones derived from human melanoma-infiltrating lymphocytes.
    Pandolfino MC; Viret C; Gervois N; Guilloux Y; Davodeau F; Diez E; Jotereau F
    Eur J Immunol; 1992 Jul; 22(7):1795-802. PubMed ID: 1623924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphocytes infiltrating human ovarian tumors: synergy between tumor necrosis factor alpha and interleukin 2 in the generation of CD8+ effectors from tumor-infiltrating lymphocytes.
    Wang YL; Si LS; Kanbour A; Herberman RB; Whiteside TL
    Cancer Res; 1989 Nov; 49(21):5979-85. PubMed ID: 2507139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enrichment in tumor-reactive CD8+ T-lymphocytes by positive selection from the blood and lymph nodes of patients with head and neck cancer.
    Letessier EM; Heo DS; Okarma T; Johnson JT; Herberman RB; Whiteside TL
    Cancer Res; 1991 Aug; 51(15):3891-9. PubMed ID: 1677310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.